BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND CRTC1, Q6UUV9, 23373, ENSG00000105662, KIAA0616, TORC1, MECT1, WAMTP1, FLJ14027 AND Treatment
7 results:

  • 1. A phase 2 and pharmacological study of sapanisertib in patients with relapsed and/or refractory acute lymphoblastic leukemia.
    Al-Kali A; Aldoss I; Atherton PJ; Strand CA; Shah B; Webster J; Bhatnagar B; Flatten KS; Peterson KL; Schneider PA; Buhrow SA; Kong J; Reid JM; Adjei AA; Kaufmann SH
    Cancer Med; 2023 Dec; 12(23):21229-21239. PubMed ID: 37960985
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
    Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
    Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
    Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Co-administration of the mtorc1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation.
    Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S
    Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. SIRT1 Suppresses Human T-Cell leukemia Virus Type 1 Transcription.
    Tang HM; Gao WW; Chan CP; Cheng Y; Deng JJ; Yuen KS; Iha H; Jin DY
    J Virol; 2015 Aug; 89(16):8623-31. PubMed ID: 26063426
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Targeting mTOR for the treatment of AML. New agents and new directions.
    Altman JK; Sassano A; Platanias LC
    Oncotarget; 2011 Jun; 2(6):510-7. PubMed ID: 21680954
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Target of rapamycin signaling in leukemia and lymphoma.
    Vu C; Fruman DA
    Clin Cancer Res; 2010 Nov; 16(22):5374-80. PubMed ID: 20826559
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.